NCT01863888 - Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Multiple Sclerosis

Interventions

DRUG

teriflunomide HMR1726

Pharmaceutical form:tablet Route of administration: oral

DRUG

cholestyramine

Pharmaceutical form:powder Route of administration: oral

DRUG

charcoal

Pharmaceutical form:granule Route of administration: oral

Trial Locations (10)

Investigational Site Number 056001, Brussels

Investigational Site Number 056002, Overpelt

Investigational Site Number 056003, Sijsele-Damme

Investigational Site Number 276-004, Hanover

Investigational Site Number 276-005, Marburg

Investigational Site Number 276-007, Mönchengladbach

Investigational Site Number 276-001, Münster

Investigational Site Number 276-002, Ulm

Investigational Site Number 276-003, Bad Mergentheim

Investigational Site Number 528001, Sittard-Geleen